MorphoSys AG

Equities

MOR

DE0006632003

Biotechnology & Medical Research

Market Closed - Xetra Other stock markets 11:37:06 2024-07-16 EDT			5-day change	1st Jan Change
67.75 ^EUR	0.00%		-0.44%	+99.26%

07-15	MorphoSys Informs Nasdaq Stock Market of Delisting Plans After Novartis Merger	MT
07-12	Novartis Seeks Squeeze Out Approval at MorphoSys AGM	MT

MorphoSys AG Provides Sales Guidance for the Financial Year 2024

January 30, 2024 at 09:56 am

MorphoSys AG provided sales guidance for the financial year 2024. For the full year of 2024, MorphoSys expects Monjuvi U.S. net product sales in the range of USD 80 to USD 95 million, aligned with the company?s original 2023 guidance.

Latest news about MorphoSys AG

MorphoSys Informs Nasdaq Stock Market of Delisting Plans After Novartis Merger	07-15	MT
Novartis Seeks Squeeze Out Approval at MorphoSys AGM	07-12	MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading	06-26	MT
INDEX-MONITOR: Tui, Rational and Traton in the MDax - Douglas moves up to the SDax	06-23	DP
MorphoSys AG(XTRA:MOR) dropped from Germany MDAX Index (Performance)	06-23	CI
MorphoSys AG(XTRA:MOR) dropped from Germany TECDAX (Total Return) Index	06-23	CI
MorphoSys AG(XTRA:MOR) dropped from Germany TECDAX Index (Price Return)	06-23	CI
Dpa-AFX Overview: COMPANIES from 20/06/2024 - 15:15	06-20	DP
Novartis: towards the filing of a buyout offer for MorphoSys	06-20	CF
MorphoSys Set to Delist Following Acquisition by Novartis	06-20	MT
MorphoSys Inks Delisting Agreement After Takeover by Novartis	06-20	MT
Biotech company Morphosys will soon disappear from the stock exchange	06-20	RE
MorphoSys to Leave Deutsche Börse’s MDAX, TecDAX Indices	06-19	MT
MorphoSys AG(XTRA:MOR) dropped from S&P Global BMI Index	06-09	CI
MorphoSys AG Announces Board Changes	06-06	CI
MorphoSys AG Appoints Arkadius Pichota as Chief Executive Officer	06-06	CI
MorphoSys AG Appoints Lukas Gilgen as CFO	06-06	CI
Three newcomers to the MDax - Rational, TUI and Traton move up	06-06	RE
European Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading	06-04	MT
SMA Solar and Morphosys are about to leave the MDax	06-03	RE
Novartis data42 AG completed the acquisition of MorphoSys AG from group of shareholders.	05-29	CI
European Equities Traded in the US as American Depositary Receipts Start Week Marginally Higher in Monday Trading	05-20	MT
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Friday Trading	05-17	MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Thursday Trading	05-16	MT
Dpa-AFX Overview: COMPANIES from 16.05.2024 - 15:15	05-16	DP

Chart MorphoSys AG

Duration

Period

More charts

Company Profile

MorphoSys AG is a global commercial-stage biopharmaceutical company based in Germany. The Company discovers, develops, and delivers cancer medicines to patients. It markets its proprietary medicine Monjuvi (tafasitamab-cxix) in the United States, a cancer immunotherapy treatment, used to treat patients in combination with lenalidomide with second and later lines of diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant. Tafasitamab is also being evaluated in a global clinical trial as a first line therapy for DLBCL. Two additional product candidates are in late and mid-stage clinical development in oncology indications: pelabresib, a small-molecule BET inhibitor, is studied as a treatment for myelofibrosis, a type of bone marrow cancer for which treatment options are limited; and CPI-0209, a second generation EZH2 inhibitor, is studied for treating hematological and solid tumors.

Sector

Biotechnology & Medical Research

Calendar

2024-08-06 - Q2 2024 Earnings Call

More about the company

Income Statement Evolution

More financial data

Ratings for MorphoSys AG

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

67.75 EUR

Average target price

58.71 EUR

Spread / Average Target

-13.34%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MORPHOSYS AG	+99.26%	2.79B
MODERNA, INC.	+25.83%	46.56B
LONZA GROUP AG	+45.38%	41.67B
IQVIA HOLDINGS INC.	+0.69%	41.16B
ALNYLAM PHARMACEUTICALS, INC.	+30.52%	32.4B
ICON PUBLIC LIMITED COMPANY	+22.30%	28.18B
CELLTRION, INC.	-6.35%	28.1B
UNITED THERAPEUTICS CORPORATION	+49.25%	14.52B
MEDPACE HOLDINGS, INC.	+49.18%	13.74B
BIO-TECHNE CORPORATION	+3.45%	12.17B

Other Biotechnology & Medical Research